Observation on therapeutic effect of erigeron breviscapus injection combined with atorvastatin calcium in the treatment of acute ischemic stroke
10.11958/20251797
- VernacularTitle:灯盏细辛注射液联合阿托伐他汀钙治疗急性缺血性脑卒中的疗效观察
- Author:
Chengcheng LI
1
;
Longxiang LI
1
;
Liheng YU
1
Author Information
1. 阜阳市人民医院中医科(邮编 236000)
- Publication Type:Journal Article
- Keywords:
ischemic stroke;
Deng Zhan Xi Xin Zhu She Ye;
Atorvastatin;
inflammation
- From:
Tianjin Medical Journal
2025;53(8):865-870
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of erigeron breviscapus injection combined with atorvastatin calcium in patients with acute ischemic stroke(AIS)and its impact on systemic inflammatory markers.Methods A total of 151 AIS patients diagnosed and treated from January 2020 to December 2022 were selected and divided into the control group(n=75)and the study group(n=76)by random number method.The control group was given oral atorvastatin calcium treatment,and the study group was additionally treated with erigeron breviscapus injection on this basis.Before treatment,7 d and 14 d after treatment,neurological function[National Institutes of Health Stroke Scale(NIHSS)],motor function[Fugl-Meyer Assessment(FMA)],activities of daily living[Barthel Index(ADL)]and systemic inflammatory markers such as tumor necrosis factor-α(TNF-α),C-reactive protein(CRP),interleukin(IL)-6,lymphocytes(LYM),white blood cells(WBC),neutrophils(NEU)and platelets(PLT)were evaluated.Efficacy evaluation was conducted after 14 days of treatment.The adverse reactions of patients during the treatment period were recorded for safety assessment.Results The NIHSS score,TNF-α,CRP,IL-6,WBC,NEU and PLT levels were lower in the study group than those in the control group after 7 d and 14 d treatment,and decreased with the increase of treatment time(P＜0.05).After 7 d and 14 d treatment,FMA score,ADL score and LYM level were higher in the study group than those in the control group,and increased with the prolongation of treatment time(P＜0.05).TNF-α,CRP,IL-6,WBC,NEU and PLT were positively correlated with NIHSS score,and negatively correlated with FMA score and ADL score.LYM was negatively correlated with NIHSS score,and positively correlated with FMA score and ADL score(P＜0.05).The total effective rate was higher in the study group than that of the control group(P＜0.05).There was no significant difference in the incidence of total adverse reactions between the two groups(P＞0.05).Conclusion After the combined treatment of AIS with erigeron breviscapus injection and atorvastatin calcium,the systemic inflammatory level of patients decreases significantly,the curative effect is good and the safety is high.
